Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis

Bostan, Ecem; Akdoğan, Neslihan; Gököz, Özay; Doğan, Sibel

doi:10.1111/dth.14531

Cited by 1 publication

(1 citation statement)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5. Urticarial vasculitis (UV) HCQ is included in the recommendations for treatment of cutaneous UV [256] • No RCT's • Several case reports and series -benefit of HCQ in hypo/normocomplementemic urticarial vasculitis with improvement in symptoms, anti-C1q antibody levels [257,258] , associated retinal vasculitis [259] , C1-esterase inhibitor concentration and activity [260] • Largest study from the French Vasculitis Study Group (n = 5) -HCQ was as effective as GC's for hypocomplementemic urticarial vasculitis [261] 6. IgA vasculitis (IgAV)/Henoch Schonlein purpura (HSP) HCQ not routinely used…”

Section: Polyarteritis Nodosa (Pan)mentioning

confidence: 99%

Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis

Jain,

Sangle,

Kim

et al. 2024

Vessel Plus

View full text Add to dashboard Cite

Antimalarial agents have been used to treat various autoimmune rheumatic diseases for over a century. Hydroxychloroquine is a safe, effective and inexpensive antimalarial drug with additional antithrombotic, cardioprotective, antimicrobial, and anti-neoplastic benefits. It has been used extensively in various diseases, especially systemic lupus erythematosus and rheumatoid arthritis; however, it has not been used in anti-neutrophil cytoplasmic antibody associated vasculitides (AAVs). There exists a significant unmet need for safe and inexpensive treatments for non-severe AAV or those with low-grade “grumbling” disease activity who do not warrant significant escalation of therapy but who remain at risk of disease flares and damage accumulation. Hydroxychloroquine may be an option to help fill this void. Although the mechanisms of action of Hydroxychloroquine are not fully understood, it interacts with various inflammatory mediators involved in the pathogenesis of AAV. Based on these benefits, along with the unmet need in AAV, we present evidence to support the use of Hydroxychloroquine as a potential therapy for AAV.

show abstract